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1078–5Objective. The clinical significance of Haemodynamic Depression (HD) during carotid stenting (CAS) remains unclear.
The aim of this study was to analyze the frequency and predictors of HD during CAS in a single centre experience.
Methods. A prospective protocol for CAS was applied in a 15-month interval. Patients with restenosis, on betablockers, or
with arrhythmias were excluded. A standardized dose of atropine (0.4 mg) was given prior to stent deployment. Changes in
heart rate, blood pressure, and neurological status were monitored and recorded. HD was defined as systolic pressure
<90 mmHg and/or heart rate <50 beats/min. Fifteen potential predictors of HD (age, gender, hypertension, smoking,
diabetes, coronary artery disease, previous myocardial infarction, symptoms, degree of carotid stenosis contralateral
CEA or CAS, calcified/hyperechoic plaque, plaque length, stent oversizing and type of stent) were tested in multivariate
analysis.
Results. Two hundred and twenty three consecutive patients were enrolled. HD occurred in 98 cases (44%): in 68 cases
HD required additional pharmacological support. At 30 days, any stroke rate was 3.1% (3 major and 4 minor), TIA rate
1.8%, myocardial infarction rate 0.4%. No deaths were recorded. No difference in complication rates were found in patients
with or without HD. From regression analysis only the presence of calcified plaque (HR 9.5; 95% CI 5.0 to 18.2;
p< 0.0001) and the plaque length (HR 1.77; 95% CI 1.03 to 3.06; p¼ 0.038) were associated significantly with HD.
Conclusions. HD during CAS is a common, relatively benign event, without increased risk of peri-operative complica-
tions. Careful pharmacological treatment is necessary to decrease HD and the potential complications, especially in patients
with more severe calcified lesions. These results require confirmation in a separate, larger cohort.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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the safety of carotid artery stenting (CAS), in compar-
ison to carotid endarterectomy (CEA), CAS is still
under clinical investigation as alternative treatment
for carotid stenosis, since it is less invasive and patient
recovery is faster.1e3 The main risks of CAS are from
cerebral embolic events with consequent neurological
deficits. Furthermore, it has been ascertained that
relevant haemodynamic changes, such as severe hy-
potension and bradycardia, may occur more fre-
quently and seriously during CAS than during CEA,
as a result of baroreflex stimulation triggered by
ballooning and stenting in the region of carotid sinus.sponding author. P. Cao, MD, FRCS, Professor of Vascular
y, University of Perugia, Chief of Vascular and Endovascular
y, Ospedale S. Maria della Misericordia, Loc. S. Andrea delle
06156 Perugia, Italy.
address: pcao@unipg.it
884/000399+ 06 $34.00/0  2007 European Society for VasculaThese haemodynamic depressions (HD), reported
in up to 68% of cases may increase the risk of
peri-procedural complications especially when
patients have severe comorbidities.4e9
The aim of the present study was to evaluate the in-
cidence and clinical relevance of HD during CAS with
respect to peri-procedural neurological and cardiac
events and to investigate factors predicting the devel-
opment of HD.Patients and Methods
A prospective protocol was applied to assess HD in to
patients undergoing CAS from March 2006 to June
2007. The institutional review board approved the
study and all patients gave informed consent.
Patients with symptomatic (>60%) or asymptom-
atic carotid stenosis (>70%) requiring treatmentr Surgery. Published by Elsevier Ltd. All rights reserved.
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also were included provided that there was at least a 1
month interval between the two staged endoluminal
interventions. To avoid interference with spontaneous
hemodynamic changes during CAS, patients with
carotid restenosis or under treatment for cardiac
rhythm disorders (including those with pace-makers)
or treated with beta-blockers were excluded. Patients
with acute or unstable symptoms also were excluded.Pre-operative evaluation
The pre-operative imaging studies consisted of
duplex ultrasound scanning (US) and selectively
Computed Tomography (CT scan or AngioCT scan).
Magnetic resonance or angiography were seldom
used. All US measurements were performed by previ-
ously validated operators who defined site, degree of
stenosis, vessel measurements and plaque morphol-
ogy, in order to correctly select devices sizes and
characteristics.
Plaque morphology was recorded at the time of ex-
amination and classified, as echolucent plaques, [de-
fined as low echogenic or non calcified plaques
appearing fully black or with spotty white areas rep-
resenting less than 25% of the total (Type 1 and 2 of
Gray-Weale)10], or hyperechoic/calcified plaques [de-
fined as high echogenic or calcified plaques, appear-
ing white or almost white with anechoic areas
representing less than 25% of the total (Type 3 and 4
of Gray-Weale)10]. The vessel lumen was used as the
reference structure for defining echolucency; the
bright echo zone produced by the media-adventitia
interface was used as the reference for defining
echogenicity.
Two carotid measurements were recorded on US:
common carotid artery (CCA: 2 cm below the bulb)
and internal carotid diameter (ICA: 2 cm above the ca-
rotid bulb or in the case of longer plaques distal to the
plaque end). The degree of stenosis, measured by US
was always confirmed with angiography at the time
of CAS procedure using the North American Symp-
tomatic Carotid Endarterectomy Trial measurements
criteria.11 All patients scheduled for CAS received
antiplatelet therapy consisting of acetylsalicylic acid
(mean dosage of 125 mg/d) and clopidogrel (75 mg/
d) after a 300 mg loading dose administered 12 hours
before CAS.
Carotid stent procedure
CAS was performed in an endovascular operating
room with high quality fixed imaging system (Axiom
Artis FA, Siemens). Patient neurological status wasEur J Vasc Endovasc Surg Vol 35, April 2008continuously monitored. Transcranial Doppler (TCD
4040 Pyoneer EME) was utilized when possible. Per-
cutaneous transfemoral or transbrachial approaches
under local anesthesia were used in all cases. Mild se-
dation was seldom used and general anesthesia never.
Cerebral protection devices (CPD) and self expand-
able stent of different models were applied in all
procedures, tailored to vessel and lesion characteris-
tics according to operator evaluation and experience.
Distal filters were preferred in cases of contralateral
occlusion or severe external carotid disease and endo-
luminal clamping systems in cases of vessel tortuosity.
Pre-dilation was used selectively.
Stent size and length were chosen according to pre-
operative measurements of the target vessel by US
examination, or by computer assisted tri-dimensional
vessel reconstruction through rotational angiography.
Stents were routinely post-dilated using a balloon
sized for the ICA (5 to 6 mm diameter balloon catheter
at a pressure of 8 to 10 atmospheres for 5 seconds). A
selective control angiography in at least 2 projections
was performed to evaluate local and intracranial
results.
Closure devices were used during the last period of
the study for access control.
Haemodynamic protocol
All patients received intrarterial pressure, cardiac
and neurological monitoring throughout the proce-
dure. According to the haemodynamic protocol, rou-
tine prophylactic atropine at a standardized dose of
0.4 mg/iv was given to all the patients before stent
deployment.
All haemodynamic changes were recorded. When
HD became symptomatic or did not spontaneously
reverse within 10’’, additional haemodynamic phar-
macologic treatment was applied. When additional
atropine and fluid administration were not sufficient,
vasopressors or inotropes were used: ethylephrine or
metaraminol as a first-line drug at increased doses,
and dopamine when needed.
Cardiac morbidity, based on cardiac enzymes and
electrocardiographic changes or clinical evidence of
congestive heart failure (CHF), were recorded.
During the first two hours after the procedure,
heart rate, non invasive oxygen saturation, pressure
measurements with a non invasive automated system
and neurological status were continuously monitored
in all patients. Subsequently these parameters were
checked on an hourly basis. Enzymes and ECG were
checked immediately and on the following morning.
The same external audit of neurologists and cardiolo-
gists evaluated evident or suspected symptoms
regardless of the occurrence of intraprocedural
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occurred, patients were discharged on the first post-
operative day under a standardized dual antiplatelet
therapy for at least 30 days, followed by a single, life-
long antiplatelet regimen. Clinical and US examina-
tion were repeated before discharge, at 1 month, and
every six months thereafter. In the case of symptoms
or uncertainty after discharge, all patients were in-
structed to inform their practitioner or the Vascular
and Endovascular Centre neurological or cardiologi-
cal consultation.
Definitions and peri-operative complications
Any symptomatic or asymptomatic hypotension (sys-
tolic blood pressure <90 mmHg) or bradycardia
(heart rate< 50 beats/min), regardless of the need
for adjunctive atropine, fluid support or vasopressor
agents, was defined HD.
Intervention was considered successful when the
procedure was completed and the residual diameter
reduction from the final angiogram was <30%.
The primary outcome measure was the occurrence
of any peri-procedural (within 30 days) stroke. The
peri-procedural occurrence of HD, disabling strokes,
death, transient ischemic attack (TIA), or myocardial
infarction (MI) were secondary outcomes.
Stroke was defined as a new neurological event
persisting >24 hours and classified as fatal, disabling
(modified Rankin Score 3) or non-disabling (modi-
fied Rankin Score <3). TIA was defined as any new
neurological focal event with complete recovery
within 24 hours. MI was diagnosed in the occurrence
of persistent ST changes and/or new Q wave in 2
leads or the presence of elevated enzymes (including
troponin> 0.1 ng/mL).
Statistical analysis. Statistical analyses were performed
using SPSS/PC version 12.00 Win package (SPSS for
Windows Chicago, IL, USA 2003). Results were con-
sidered to be statistically significant at p< 0.05. Base-
line characteristics of patients with and without HD
were compared using c2 and t tests. Patients were
stratified according to the presence of HD and out-
come differences were measured as Odds Ratio (OR)
with corresponding 95% Confidence Interval (CI). Pa-
tients with HD requiring pharmacological support
were compared to those without HD.
Logistic regression analysis was used to determine
the variables that independently predicted patients
developing HD and HD requiring pharmacological
support. The following risk factors for HD were
included in the model: age, gender, hypertension,
smoking, diabetes, coronary artery disease, previous
myocardial infarction, previous symptoms, degree ofcarotid stenosis, contralateral CEA, contralateral
CAS, calcified/hyperchoic plaque, plaque length,
stent oversizing and type of stent (open versus closed
design). Backward stepwise logistic regression analy-
sis was applied to selected variables in the multivari-
ate models. Results were reported as hazard ratios
(HR) with corresponding 95% CI.Results
Of a total of 387 consecutive patients undergoing CAS
during the study period, 223 primary carotid stenoses
were eligible for inclusion in the prospective protocol
for haemodynamic assessment and represent the
study population.The mean age was 71 7.4 years
and 69% were men. The study included both symp-
tomatic (N¼ 63; 28%) and asymptomatic patients
(N¼ 160; 72%).
The following CPDs were used: FilterWire EZ sys-
tem, Boston Scientific, Natick, MA,USA (n 179, 80.3%);
MO.MA system, Invatec, Brescia, Italy (n 19, 8.5%);
Angioguard RX Filter, Johnson and Johnson-Cordis,
Warren, NJ, USA (n 12, 5.3%); Emboshield Filter,
Abbott Laboratories, Abbott Park, Illinois, USA, (n 5,
2.3%); Rx Accunet Filter, Guidant, Santa Clara, CA,
USA (n 3, 1.3%); Rubicon Filter, Rubicon Medical
Inc., Salt Lake City, UT, USA (n 3, 1.3%); SpideRX Fil-
ter, EV3, Plymouth, MN, USA (n 2, 1%). Pre-dilation
was performed in 49 vessels (22%).
Self-expandable stents were close cell design/
elgiloy fabric in 177 cases (79.3%) [Carotid Wallstents
(Boston Scientific Corp., Natick, MA, USA)] and
open cell/nitinol made in 45 (20.3%) [Precise stents
(Johnson and Johnson-Cordis, Warren, NJ, USA)]. Fur-
thermore, 1 (0.4%), multidesigned nitinol stent was
used (Cristallo Ideale stent; Invatec, Brescia, Italy).
The procedure was technically successful in all 223
cases.Adverseperi-procedural events occurred in 8 pa-
tients (3.6%). There were 3 disabling (1.3%), and 4 non-
disabling (1.8%) strokes, 4 TIAs and 1 MI. No deaths
and no episodes of CHFwere recordedwithin 30 days.
The overall incidence of HD was 98/223 (44%). Hy-
potension occurred in 68 (30.5%), bradycardia devel-
oped during 95 (42.6%) procedures, and isolated
bradycardia without hypotension in 30 (13.4%). Asys-
tole occurred in 20 patients (8.9%). In 68 of the 98
patients developing HD (69.4%) adjunctive atropine
or vasopressor treatment was required.
The characteristics of patients with and without
HD are shown in Table 1. Atherosclerotic hypere-
choic/calcific and longer plaques were significantly
more frequent in HD and HD requiring further phar-
macologic support. None of the remaining clinicalEur J Vasc Endovasc Surg Vol 35, April 2008
Table 1. Characteristics of patients with and without HD
No HD (n 125) HD (n 98) P value HD requiring
support (n 68)
P value*
Age (Mean) 71.1 70.7 0.79 70.2 0.97
Male gender 84 (67.2%) 70 (71.4%) 0.56 51 (75%) 0.33
Hypertension 110 (88%) 84 (85.7%) 0.37 58 (88.3%) 0.75
Smoking habit 76 (60.8%) 64 (65.3%) 0.57 45 (66.1%) 0.56
Coronary artery disease 37 (29.6%) 30 (30.6%) 0.88 22 (32.3%) 0.81
Previous MI 14 (11.2%) 15 (15.3%) 0.42 13 (19.1%) 0.19
Symptoms 38 (30.4%) 25 (25.5%) 0.45 15 (22%) 0.28
Diabetes 41 (32.8%) 38 (38.7%) 0.39 26 (38.2%) 0.54
Controlateral CEA 9 (7.2%) 5 (5.1%) 0.58 3 (4.4%) 0.54
Controlateral CAS 7 (5.6%) 7 (7.1%) 0.78 5 (7.3%) 0.75
Hyperechoic/calcific plaque 40 (32%) 80 (81.6%) <0.0001 57 (83.8%) <0.0001
Close cell stent 98 (78.,4%) 79 (80.6%) 0.74 54 (79.4%) 0.98
Lesion length cm (mean) 1.78 1.96 0.007 1.97 <0.0001
Stenosis % (mean) 78.6 79.2 0.7 79.5 0.52
HD: hemodynamic depression; MI: myocardial infarction; CEA: caratid endarterectomy; CAS: carotid artery stenting.
* HD requiring support vs no HD.
402 E. Cieri et al.baseline and morphologic factors were significantly
associated with HD. In particular, the rates of cardiac
risk factors (history of myocardial infarction, unstable
angina, or coronary disease) were similar in HD and
non HD patients.
The distribution of clinical outcomes for patients
with and without HD is shown in Table 2. There
were no significant differences between patients
with and without HD (or HD requiring pharmacolog-
ical support) in the rates of stroke, MI, or any major
adverse clinical event (Table 2). In particular, no MI
or CHF occurred in the HD group. Four of 98 patients
with HD showed protracted HD (persistant and re-
quiring further support after the end of the proce-
dure), no complications occurred in these patients.
Furthermore, patients with HD did not have a longer
post-operative stay due to protracted or severe HD
(1.22 days for HD vs. 1.09 days for non HD group;
p¼ 0.6).
In multivariate analysis, the presence of hypere-
choic/calcified plaque was a predictor for both HD
(HR 9.5; 95% CI 5.0 TO 18.2; p< 0.0001) and HD re-
quiring further support (HR 8.1; 95% CI 3.9 to 16.92;
p< 0.0001). Plaque length was a more marginal pre-
dictor of HD (HR 1.77; 95% CI 1.03 to 3.06;Table 2. Clinical Outcomes n patients with and without HD
No HD (125) HD (98) P value
Any stroke 3 (2.4%) 4 (4%) 0.7
Major stroke 2 (1.6%) 1 (1%) 1
TIA 4 (3.2%) 0 0.1
MI 1 (0.8%) 0 1
MACE 4 (3.2%) 4 (4%) 0.73
HD: hemodynamic depression; TIA: transient ischemic attack; MI:
myocardial infarction.
MACE: major adverse clinical events.
Eur J Vasc Endovasc Surg Vol 35, April 2008p¼ 0.038). There were no other significant predictors
for HD or HD with support (Table 3).Discussion
In this study, about half (44%) of patients experienced
bradycardia or hypothension during the procedure. It
has been suggested that more one factor is able to trig-
ger the baroreflex in the carotid sinus region causing
haemodynamic instability during CAS. Stretch ap-
plied to carotid artery by balloon dilatation generally
is accepted as transient and easily resolved. However,
stents may cause prolonged pressure transmission
against the carotid sinus resulting in a more pro-
nounced baroreflex response, which may not be pre-
vented with atropine. Furthermore, other local
factors (e.g., oversizing and length of carotid stent,
higher radial force from different stent design) are
suggested as adjuncts able to influence the unpredict-
ability of baroreflex response.
In our experience two types of acute HD were iden-
tifiable. The first involved transient and self-resolving
episodes not requiring pharmacological adjunct to the
prophylactic dose of 0.4 mg/i.v. of atropine. The
second pattern, that most frequently encountered
(68/98), showed a prolonged and more severe courseTable 3. Multivariate analysis of predictors on HD and HD
requiring support (Backward method)
Predictors of HD HR P value 95% C.I.
Hyperechoic/calcific plaque 9.593 <0.0001 5.039 18.260
Lesion length 1.779 0.038 1.034 3.061
Predictors of HD requiring support
Hyperechoic/calcific plaque 8.143 <0.0001 3.917 16.928
HD: hemodynamic depression.
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these patterns appeared to be unrelated to the
patients’ underlying cardiac condition. Other studies
have suggested that patients with a history of signifi-
cant cardiac risk factors may have increased barore-
ceptor sensitivity and are more likely to develop
HD.7,12,13 Others have reported age or local variables
(plaque length, site, calcification, stent size and con-
tralateral stenosis) as predictors of increased dysfunc-
tion of baroreceptors.14e17
Our data suggest that only local factors (highly
calcified and longer plaque) are associated with
a higher probability of HD (HR 9.59; 95% CI 5.0 to
18.26; P< 0.0001 and HR 1.77; 95% CI 1.0 to 3.0;
P< 0.038). Presumably, heavily calcified plaques are
more prone to HD because the baroreceptors, usually
exposed to dampened pressure waves, receive a sud-
den and extraordinary stimulation by radial force due
to balloon dilation.18 The longer the plaque, the higher
the number of baroreceptors dampened. It has also
been suggested that calcified plaques require more
aggressive balloon inflation, triggering an amplified
baroreflex response. However, in this study inflation
pressure ranges were too narrow (6-8 atmospheres
for a maximum of 5 seconds) to justify such an
hypothesis. Nevertheless,, even in severe HD there
was no increased risk of adverse cerebrovascular or
cardiac events. Other local factors (oversizing of
stented artery, higher radial force from close cell elgi-
loy fabric, contralateral occlusion) were not associated
to higher probability of HD in our study. It could be
that the effect of these variables on baroreflex re-
sponse is minor and may be easily controlled with
prophylactic doses of atropine and accuracy in de-
ployment manoeuvres.
There has been considerable debate in literature
with regards to HD as a predictor of adverse events.
Some studies have suggested that HD may lead to
a greater incidence of peri-procedural complications,
and even death.6,9,14 However, in other studies only
few patients developing HD experienced complica-
tions from CAS.4,16 Our results support these latter
findings. Patients with HD, a common condition,
did not show any increase in cardiac or neurological
adverse events. Cayne et al. found an overall 33% in-
cidence of hypotension/bradycardia with no evidence
of clinical stroke or death over 75 CAS patients, and
cardiac morbidity was reduced by the use of prophy-
lactic atropine.4 On the other hand, Gupta et al., on 500
CAS, found an increased probability not only of peri-
procedural stroke (OR 3.34; 95%CI 1.13 to 9.90) but
also of myocardial infarction and death (OR 3.05;
95%CI 1.35 to 5.23; P< 0.02) in patients with ‘‘persis-
tent HD’’ requiring continuous vasopressor infusion.8The differences in study results are obviously due
to several factors such as patient selection and the
criteria used to define the severity and persistency
of HD. Furthermore, haemodynamic changes in CAS
patients at higher surgical risk, because of severe cor-
onary or controlaterateral carotid disease, may skew
the occurrence of clinically relevant events. The di-
minished cardiovascular reserve and the comorbid-
ities inherent to this particular patient population
mandate the effort to optimize the haemodynamic
status prior, during, and after the procedure.
This study did not support intra-operative hypo-
tension as a predictor of post-operative hypotension,
as reported by others.7,13 Hypotension was protracted
in only a few cases (n¼ 4) and did not expose patients
to increased post-procedural risk of stroke or longer
hospital stay.
The mechanism for stroke in patients who experi-
ence periprocedural HD, as reported by other studies,
is presumed due to hypotension that decreases the
washout of embolic debris (originating from balloon
inflation and stent delivery) in the distal intracranial
circulation and dampens the appropriate collateral
flow from ischemic territories.13,19 Appropriate expe-
rience in preventing embolic events as well as quick
intervention of trained anesthesiologists play a crucial
role in achieving a good outcome in patients experi-
encing HD.20
Invasive monitoring of haemodynamic changes
was discontinued after the procedure, however non
invasive control of haemodynamic and neurological
status was maintained throughout the whole postop-
erative period, giving enough time to detect all the
relevant HD changes which might have occurred.
Some kinds of patients (i.e. restenosis, on beta-
blockers, etc.) were excluded from the protocol be-
cause in this group HD changes may be undetectable
or unreliable.13 However, the peri-procedural risk
found in the study population was comparable to
that shown in the entire 387 CAS cohort of the study
period: overall major complication rate 15/387
(3.78%); disabling stroke rate 6/387 (1.55%);
non-disabling stroke rate 7/387 (1.8%); myocardial
infarction 2/387 (0.5%). This could suggest that pro-
phylactic atropine effects the same level of decreased
baroreceptors sensitivity as obtained by previous sur-
gical removal (restenosis after CEA) or pharmacolog-
ical block.
Since all patients received a prophylactic low dose of
atropine, we cannot assess the potential effect of this
drug in preventing HD in comparison to other treat-
ment regimens. However, the prophylactic use of atro-
pine has been incorporated in many CAS protocols
and recommended by AHA Consensus document.21Eur J Vasc Endovasc Surg Vol 35, April 2008
404 E. Cieri et al.Potential limitations include the small number of
recorded adverse outcomes, which reduces the pre-
dictive ability in multivariate models, and the lack
of a specific calcium score to assess the stiffness of ca-
rotid plaque.
Conclusions
The incidence of HD during CAS is high, particularly
in the presence of calcified and long carotid plaques.
No other clinical or technical factors appear to influ-
ence the occurrence of HD, Baroreflex response, as
a physiologic response, cannot be inhibited by drug
treatment. HD (even when severe or long) does not
appear to predispose to peri-procedural adverse
events. Early recognition of HD (e.g., presence of
long, calcified plaque) and prompt treatment play
a crucial role in achieving good CAS outcomes.
Acknowledgements
We would like to thank Francesca Zannetti and Eileen
Mahoney for editorial assistance.References
1 MAS JL, CHATELLIER G, BEYSSEN B, BRANCHEREAU A, MOULIN T,
BECQUEMIN JP et al., for the EVA-3S Investigators. Endarterectomy
versus stenting in patients with symptomatic severe carotid
stenosis. N Engl J Med 2006;355:1660e1671.
2 YADAV JS, WHOLEY MH, KUNTZ RE, FAYAD P, KATZEN BT,
MINSHKEL GJ et al., for the Stenting and Angioplasty with Protec-
tion in Patients at HIgh Risk for Endarterectomy Investigators.
Protected carotid-artery stenting versus endarterectomy in
high-risk patients. N Engl J Med 2004;351:1493e1501.
3 The SPACE Collaborative Group. 30 day results from the SPACE
trial of stent-protected angioplasty versus carotid endarterec-
tomy in symptomatic patients: a randomized non-inferiority
trial. Lancet 2006;368:1239e1247.
4 CAYNE NS, FARIES PL, TROCCIOLA SM, SALTZBERG SS, DAYAL RD,
CLAIR D et al. Carotid angioplasty and stent-induced bradycardia
and hypotension: impact of prophylactic atropine administra-
tion and prior carotid endarterectomy. J Vasc Surg 2005 Jun;
41(6):956e961.
5 MENDELSOHN FO, WEISSMAN NJ, LEDERMAN RJ, CROWLEY JJ, GRAY JL,
PHILLIPS HR et al. Acute hemodynamic changes during carotid
artery stenting. Am J Cardiol 1998 Nov 1;82(9):1077e1081.
6 HOWELL M, KRAJCER Z, DOUGHERTY K, STRICKMAN N, SKOLKIN M,
TOOMBS B et al. Correlation of periprocedural systolic blood pres-
sure changes with neurological events in high-risk carotid stent
patients. J Endovasc Ther 2002 Dec;9(6):810e816.
7 QURESHI AI, LUFT AR, SHARMA M, JANARDHAN V, LOPES DK, KHAN J
et al. Frequency and determinants of postprocedural hemody-
namic instability after carotid angioplasty and stenting. Stroke
1999 Oct;30(10):2086e2093.Eur J Vasc Endovasc Surg Vol 35, April 20088 GUPTA R, ABOU-CHEBL A, BAJZER CT, SCHUMACHER HC, YADAV JS.
Rate, predictors, and consequences of hemodynamic depression
after carotid artery stenting. J Am Coll Cardiol 2006 Apr 18;47(8):
1538e1543.
9 PARK B, SHAPIRO D, DAHN M, ARICI M. Carotid artery angioplasty
with stenting and postprocedure hypotension. Am J Surg 2005
Nov;190(5):691e695.
10 GRAY-WEALE AC, GRAHAM JC, BURNETT JR, BYRNE K, LUSBY RJ.
Carotid artery atheroma: comparison of preoperative B-
mode ultrasound appearance with carotid endarterectomy
specimen pathology. J Cardiovasc Surg (Torino) 1988;29:
676e681.
11 NASCET Collaborators. Beneficial effect of carotid endarterec-
tomy in symptomatic patients with high-grade carotid stenosis.
Nort American Symptomatic Carotid Endarterectomy Trial
Collaborators. N Engl J Med 1991;325:445e453.
12 TROCCIOLA SM, CHAER RA, LIN SC, RYER EJ, DE RUBERTIS B,
MORRISSEY NJ et al. Analysis of parameters associated with hypo-
tension requiring vasopressor support after carotid angioplasty
and stenting. J Vasc Surg 2006;43(4):714e720.
13 GUPTA R, HOROWITZ M, JOVIN TG. Hemodynamic instability
after carotid artery angioplasty and stent placement: a review
of the literature. Neurosurg Focus 2005 Jan 15;18(1):e6
[Review].
14 DANGAS G, LAIRD Jr JR, SATLER LF, MEHRAN R, MINTZ GS, LARRAIN G
et al. Postprocedural hypotension after carotid artery stent place-
ment: predictors and short- and long-term clinical outcomes.
Radiology 2000 Jun;215(3):677e683.
15 LEISCH F, KERSCHNER K, HOFMANN R, STEINWENDER C, GRUND M,
BIBL D et al. Carotid sinus reactions during carotid artery stent-
ing: predictors, incidence, and influence on clinical outcome.
Catheter Cardiovasc Interv 2003 Apr;58(4):516e523.
16 MLEKUSCH W, SCHILLINGER M, SABETI S, NACHTMANN T, LANG W,
AHMADI R et al. Hypotension and bradycardia after elective
carotid stenting: frequency and risk factors. J Endovasc Ther
2003 Oct;10(5):851e859.
17 NONAKA T, OKA S, MIYATA K, MIKAMI T, KOYANAGI I, HOUKIN K et al.
Prediction of prolonged postprocedural hypotension after
carotid artery stenting. Neurosurgery 2005;57(3):472e477.
18 DANGAS G. Editorial comment. Hypotension after carotid revas-
cularization. Stroke 2003;34:2581e2582.
19 CAPLAN LR, HENNERICI M. Impaired clearance of emboli (wash-
out) is an important link between hypoperfusion, embolism,
and ischemic stroke. Arch Neurol 1998 Nov;55(11):1475e1482
[Review].
20 VERZINI F, CAO P, DE RANGO P, PARLANI G, MASELLI A, ROMANO L
et al. Appropriateness of learning curve for carotid artery
stenting: an analysis of periprocedural complications. J Vasc
Surg 2006;44(6):1205e1211.
21 American College of Cardiology Foundation, American Society
of Interventional & Therapeutic Neuroradiology, Society for
Cardiovascular Angiography and Interventions, Society for
Vascular Medicine and Biology, Society of Interventional Radi-
ology, BATES ER, BABB JD, CASEY Jr DE, CATES CU,
DUCKWILER GR, FELDMAN TE et al. ACCF/SCAI/SVMB/SIR/
ASITN 2007 clinical expert consensus document on carotid
stenting: a report of the American College of Cardiology
Foundation Task Force on Clinical Expert Consensus Docu-
ments (ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Con-
sensus Document Committee on Carotid Stenting). J Am Coll
Cardiol 2007;49(1):126e170.
Accepted 26 October 2007
Available online 21 February 2008
